Dermatology · New Haven, CT
NPI
1609058080
Since 2007
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
2 Church St S, Yale Dermatology Associates
New Haven, CT, 06519
Phone (203) 789-1249
Groups this clinician bills Medicare through
Medicare paid, 2024
$31K
800 services
Medicare patients, 2024
122
Average age 75
Drug cost, 2024
$2.2M
749 prescriptions
Company payments, 2025
$2,091
From 6 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Keith A Choate was code 17003 (destruction skin lesion), 343 times for 38 patients. In total Keith A Choate billed 800 services in 21 codes, and Medicare paid $31K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 17003 Destruction Skin Lesion | Office | 343 | 38 | $5.60 | $1,920 |
| 99213 Office E&M - Established | Office | 164 | 100 | $71.12 | $12K |
| 17000 Destruction Skin Lesion | Office | 76 | 45 | $41.20 | $3,132 |
| 11102 Skin Biopsy | Office | 60 | 47 | $64.45 | $3,867 |
| 17110 Destruction Skin Lesion | Office | 35 | 28 | $86.18 | $3,016 |
| 99214 Office E&M - Established | Office | 33 | 24 | $97.80 | $3,228 |
By year: 2022 $64K for 1,446 services; 2023 $35K for 850 services; 2024 $31K for 800 services.
Medicare prescription drug claims, 2024
In 2024, the drug Keith A Choate prescribed most often to Medicare patients was Acitretin, with 69 prescriptions and refills. In total Keith A Choate wrote 749 Medicare prescriptions that cost $2.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Acitretin Generic | 69 | 76 | Under 11 | $27K |
| Clobetasol Propionate Generic | 65 | 71 | 39 | $2,402 |
| Triamcinolone Acetonide Generic | 62 | 81 | 33 | $740 |
| Dupixent Pen Dupilumab | 37 | 42 | Under 11 | $162K |
| Valacyclovir Valacyclovir Hcl | 33 | 41 | 11 | $1,228 |
| Taltz Autoinjector Ixekizumab | 28 | 37 | Under 11 | $286K |
| Skyrizi Pen Risankizumab-Rzaa | 27 | 73 | Under 11 | $576K |
| Hydrocortisone Generic | 27 | 31 | 19 | $187 |
| Ketoconazole Generic | 25 | 27 | 16 | $337 |
| Tremfya Guselkumab | 24 | 38 | Under 11 | $330K |
| Tacrolimus Generic | 18 | 24 | 13 | $1,879 |
| Cephalexin Generic | 17 | 17 | Under 11 | $126 |
| Claravis Isotretinoin | 16 | 16 | Under 11 | $975 |
| Mupirocin Generic | 16 | 20 | Under 11 | $148 |
| Fluorouracil Generic | 16 | 16 | Under 11 | $618 |
Brand drugs: 232 claims; generic drugs: 517 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Keith A Choate $2,091 ($2,091 in general payments such as food, travel and fees) from 6 companies. The largest payer was BioCryst Pharmaceuticals, Inc. with $2,091.
| Company | Payments | Amount |
|---|---|---|
| BioCryst Pharmaceuticals, Inc. BCRX | 1 | $2,091 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.